The estimated Net Worth of Ltd Bio Cell is at least $21.3 Milion dollars as of 13 August 2014. Ltd Cell owns over 4,400,000 units of Protalix BioTherapeutics stock worth over $10,468,972 and over the last 10 years Ltd sold PLX stock worth over $10,868,000.
Ltd has made over 1 trades of the Protalix BioTherapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently Ltd sold 4,400,000 units of PLX stock worth $10,868,000 on 13 August 2014.
The largest trade Ltd's ever made was selling 4,400,000 units of Protalix BioTherapeutics stock on 13 August 2014 worth over $10,868,000. On average, Ltd trades about 2,200,000 units every 0 days since 2014. As of 13 August 2014 Ltd still owns at least 10,066,319 units of Protalix BioTherapeutics stock.
You can see the complete history of Ltd Cell stock trades at the bottom of the page.
Ltd's mailing address filed with the SEC is MOSHE AVIV TOWER, 7 ZABOTINSKY STREET, RAMAT GAN, L3, 52520.
Over the last 18 years, insiders at Protalix BioTherapeutics have traded over $46,705,936 worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth $4,673,005 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Capital Management Lp Camber a Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $404,231. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth $90,322.
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase
Protalix BioTherapeutics executives and other stock owners filed with the SEC include: